Cover Image
市場調查報告書

季節性過敏性鼻炎:開發中產品分析

Seasonal Allergic Rhinitis - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 245991
出版日期 內容資訊 英文 49 Pages
訂單完成後即時交付
價格
Back to Top
季節性過敏性鼻炎:開發中產品分析 Seasonal Allergic Rhinitis - Pipeline Review, H2 2016
出版日期: 2016年08月17日 內容資訊: 英文 49 Pages
簡介

所謂季節性過敏性鼻炎(花粉症)是空氣中夾帶的花粉造成的疾病。主要的症狀有口、鼻、喉嚨、眼睛發癢,及鼻涕·鼻塞,催淚,黑眼圈等。致病因素有年齡及家族病史、其他過敏症狀存在等。主要的治療藥包含皮質類固醇和抗組織胺藥物,充血緩和劑(鼻塞藥)等。

本報告提供全球各國治療季節性過敏性鼻炎所用的開發中產品開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

季節性過敏性鼻炎概要

治療藥的開發

  • 季節性過敏性鼻炎開發中產品:概要

各企業開發中的季節性過敏性鼻炎治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品

季節性過敏性鼻炎治療藥:開發中的產品一覽(各企業)

季節性過敏性鼻炎治療藥的開發企業

  • Allergy Therapeutics Plc
  • Faes Farma, S.A.
  • Glenmark Pharmaceuticals Ltd.
  • 久光製藥
  • Merck & Co., Inc.
  • Pfizer Inc.
  • 鹽野義製藥
  • VentiRx Pharmaceuticals, Inc.

季節性過敏性鼻炎:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

季節性過敏性鼻炎治療藥:開發暫停的產品

季節性過敏性鼻炎治療藥:開發中止的產品

季節性過敏性鼻炎相關產品的開發的里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8364IDB

Summary

Global Markets Direct's, 'Seasonal Allergic Rhinitis - Pipeline Review, H2 2016', provides an overview of the Seasonal Allergic Rhinitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Seasonal Allergic Rhinitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Seasonal Allergic Rhinitis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Seasonal Allergic Rhinitis
  • The report reviews pipeline therapeutics for Seasonal Allergic Rhinitis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Seasonal Allergic Rhinitis therapeutics and enlists all their major and minor projects
  • The report assesses Seasonal Allergic Rhinitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Seasonal Allergic Rhinitis

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Seasonal Allergic Rhinitis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Seasonal Allergic Rhinitis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Seasonal Allergic Rhinitis Overview
  • Therapeutics Development
    • Pipeline Products for Seasonal Allergic Rhinitis - Overview
  • Seasonal Allergic Rhinitis - Therapeutics under Development by Companies
  • Seasonal Allergic Rhinitis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
  • Seasonal Allergic Rhinitis - Products under Development by Companies
  • Seasonal Allergic Rhinitis - Companies Involved in Therapeutics Development
    • Allergy Therapeutics Plc
    • Faes Farma, S.A.
    • Glenmark Pharmaceuticals Ltd.
    • Hisamitsu Pharmaceutical Co., Inc.
    • Merck & Co., Inc.
    • Pfizer Inc.
    • Shionogi & Co., Ltd.
    • VentiRx Pharmaceuticals, Inc.
  • Seasonal Allergic Rhinitis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • asapiprant - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • bilastine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • desloratadine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • emedastine difumarate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSP-301 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PF-06444752 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PF-06444753 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Pollinex Quattro Tree - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VTX-1463 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Seasonal Allergic Rhinitis - Dormant Projects
  • Seasonal Allergic Rhinitis - Discontinued Products
  • Seasonal Allergic Rhinitis - Product Development Milestones
    • Featured News & Press Releases
      • May 09, 2016: Allergy Therapeutics Announces Positive Top-Line Results From the PQBirch204 Phase II Study for Birch-Induced Seasonal Allergic Rhinitis
      • Apr 25, 2016: Aralez Receives Health Canada Approval For BLEXTEN
      • Oct 11, 2013: FDA Approves Sanofi's Nasacort Allergy 24HR for Over-the-Counter Use
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Seasonal Allergic Rhinitis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Seasonal Allergic Rhinitis - Pipeline by Allergy Therapeutics Plc, H2 2016
  • Seasonal Allergic Rhinitis - Pipeline by Faes Farma, S.A., H2 2016
  • Seasonal Allergic Rhinitis - Pipeline by Glenmark Pharmaceuticals Ltd., H2 2016
  • Seasonal Allergic Rhinitis - Pipeline by Hisamitsu Pharmaceutical Co., Inc., H2 2016
  • Seasonal Allergic Rhinitis - Pipeline by Merck & Co., Inc., H2 2016
  • Seasonal Allergic Rhinitis - Pipeline by Pfizer Inc., H2 2016
  • Seasonal Allergic Rhinitis - Pipeline by Shionogi & Co., Ltd., H2 2016
  • Seasonal Allergic Rhinitis - Pipeline by VentiRx Pharmaceuticals, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Seasonal Allergic Rhinitis - Dormant Projects, H2 2016
  • Seasonal Allergic Rhinitis - Dormant Projects (Contd..1), H2 2016
  • Seasonal Allergic Rhinitis - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Seasonal Allergic Rhinitis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top